Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425008 · ClinicalTrials.gov registry record · Phase 1
Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 149
- Enrollment target
NCT01425008 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 149 participants.
The verdict
NCT01425008, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 149 participants
- Enrollment target
Study Summary
This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard therapies or for whom no approved therapy is available. The Dose Expansion phase will include participants with metastatic melanoma.
Interventions
- DRUG MLN2480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2011-09-15 |
| Est. Completion | 2018-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01425008
The ClinicalTrials.gov registry entry for NCT01425008 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MLN2480 is the first listed.
NCT01425008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01425008 about?
NCT01425008 is a clinical study titled "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma". This is a phase 1, multicenter, nonrandomized, open-label, dose escalation study. The study will be conducted in 2 stages, Dose Escalation and Dose Expansion. The Dose Escalation phase will include participants with solid tumors (including melanoma) who have failed or are not candidates for standard...
What is the current status of trial NCT01425008?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 149 participants. The study started on 2011-09-15. Estimated completion is 2018-10-16.
What interventions are being tested in trial NCT01425008?
The interventions under investigation include: MLN2480 (DRUG).
Who is sponsoring clinical trial NCT01425008?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.